Trauma (Emergency, Injury, Surgery)

Avita Medical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL® System for Pediatric Scald Injuries

Lead Product(s): Autologous regenerative epidermal cells

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2020

Details:

This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely increase the healing at day 10.

Pluristem Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposa

Lead Product(s): PLX-R18

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel. Other factors included BARDA’s current strategic needs, availability of funds and resources.

Abigo Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB

Lead Product(s): Dialkylcarbamoylchloride

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Essity

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition February 27, 2020

Details:

ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals Announces Proposed Public Offering

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Guggenheim Securities

Deal Size: $21.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 20, 2020

Details:

EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals and Vision Center Network Ink Agreement

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Vision Center Network of America

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 18, 2020

Details:

The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

Ocumension inks $14M deal with EyePoint Pharma

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Ocumension Therapeutics

Deal Size: $14.0 million Upfront Cash: $2.0 million

Deal Type: Licensing Agreement February 03, 2020

Details:

Ocumension will receive exclusive rights to develop and commercialize the product in Mainland China, Hong Kong, Macau and Taiwan.

Vasopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)

Lead Product(s): Ronopterin

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.

Odyssey Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates

Lead Product(s): PRV-002

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

Prevacus, has completed GMP certification of API for their lead compound for treating concussion and is now preparing the final nano-formulation for nasal application to initiate its first human trials.

Inotrem S.A

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

EYEFORPHARMA

Participation Not Confirmed

Update your events

Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock

Lead Product(s): Nangibotide

Therapeutic Area: Trauma (Emergency, Injury, Surgery)

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Roche Diagnostics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 21, 2020

Details:

Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.